- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03686228
Treatment of No-option CLI by G-CSF-mobilized PB-MNC
December 16, 2021 updated by: Mahidol University
Treatment of No-option CLI Patients by G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells
This study will investigate the efficacy of G-CSF mobilized mononuclear cell injection of patients with PAD who presented with no-option CLI.
Forty no-option CLI patients who presented with rest pain, non-healing ischemic ulcer or gangrene will be randomized into 2 groups.
The control group will be treated by medication and supportive treatment.
The experiment group will be injected G-CSF mobilized mononuclear cell ,medication.
Amputation free survival,Ankle brachial index(ABI), Toe brachial index (TBI) and transcutaneous oxygen measurement will be evaluated at the day of randomization, 1 , 3, 6 and 12 months.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This study will investigate the efficacy of G-CSF mobilized mononuclear cell injection of patients with PAD who presented with no-option CLI.
Forty no-option CLI patients who presented with rest pain, non-healing ischemic ulcer or gangrene will be randomized into 2 groups.
The control group will be treated by medication and supportive treatment.
The experiment group will be injected G-CSF mobilized mononuclear cell ,medication.
Ankle brachial index(ABI), Toe brachial index (TBI) and transcutaneous oxygen measurement will be evaluated at the day of randomization, 1 , 3, 6 and 12 months in the control group and day of randomization, 1 , 3, 6 and 12 months after injection of PB-MNC in the experiment group.
Amputation free survival will be evaluated at , 1 , 3, 6 and 12 months after PB-MNC therapy.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nuttawut SERMSATHANASAWADI
- Phone Number: +66851118278
- Email: nuttawut@gmail.com
Study Locations
-
-
Bangkok
-
Bangkoknoi, Bangkok, Thailand, 10700
- Recruiting
- Vascular Surgery, Siriraj Hospital, Mahidol University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with no-option CLI who presented with rest pain , non-healing ischemic ulcer and toe gangrene for 3 months
Exclusion Criteria:
- Recent myocardial infarction
- Severe valvular heart disease
- After organ transplantation
- Cardiomyopthy( EF< 25%)
- Liver failure
- Coagulopathy
- HIV
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: PB-MNC therapy
The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb and Aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
|
The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day.
The mononuclear cell will be collected by blood cell separator.
The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge.
Patients will receive ASA 81 mg once daily and wound care and pain killer drug
|
|
ACTIVE_COMPARATOR: No PB-MNC therapy
In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
|
Patients will receive ASA 81 mg once daily and wound care and pain killer drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amputation free survival
Time Frame: 3 month
|
Rate of non amputated limb
|
3 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ankle brachial index (ABI)
Time Frame: 1,3,6,12 month
|
Ankle brachial indexThe Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm.
It has been shown to be a specific and sensitive metric for the diagnosis of Peripheral Arterial Disease (PAD)
|
1,3,6,12 month
|
|
Toe brachial index (TBI)
Time Frame: 1,3,6,12 month
|
Toe brachial indexThe toe brachial index is the ratio between toe pressure and the highest of the two brachial pressures
|
1,3,6,12 month
|
|
Transcutaneous oxygen measurement (TCOM)
Time Frame: 1,3,6,12 month
|
Transcutaneous oxygen measurement
|
1,3,6,12 month
|
|
36-Item Short Form Health Survey (SF36)
Time Frame: 1,3,6,12 month
|
SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
These measures rely upon patient self-reporting.
|
1,3,6,12 month
|
|
Amputation free survival
Time Frame: 1,6,12 month
|
Rate of non amputated limb
|
1,6,12 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nuttawut SERMSATHANASAWADI, Mahidol university
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2018
Primary Completion (ANTICIPATED)
December 31, 2023
Study Completion (ANTICIPATED)
December 31, 2023
Study Registration Dates
First Submitted
September 25, 2018
First Submitted That Met QC Criteria
September 25, 2018
First Posted (ACTUAL)
September 26, 2018
Study Record Updates
Last Update Posted (ACTUAL)
December 17, 2021
Last Update Submitted That Met QC Criteria
December 16, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SI016033012/2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.